A new set of binuclear arene ruthenium complexes [Ru2(p-cymene)2(k4-N2OS)(L1-L3)Cl2] (Ru
2
L1–Ru
2
L3) encompassing furan-2-carboxamide-based aroylthiourea derivatives
(H
2
L1–H
2
L3) was synthesized and characterized
by various spectral and analytical techniques. Single-crystal XRD
analysis unveils the N^O and N^S mixed monobasic bidentate coordination
of the ligands constructing N, S, Cl/N, O, and Cl legged piano stool
octahedral geometry. DFT analysis demonstrates the predilection for
the formation of stable arene ruthenium complexes. In vitro antiproliferative activity of the complexes was examined against
human cervical (HeLa), breast (MCF-7), and lung (A549) cancerous and
noncancerous monkey kidney epithelial (Vero) cells. All the complexes
are more efficacious against HeLa and MCF-7 cells with low inhibitory
doses (3.86–11.02 μM). Specifically, Ru
2
L3 incorporating p-cymene and -OCH3 fragments exhibits high lipophilicity,
significant cytotoxicity against cancer cells, and lower toxicity
on noncancerous cells. Staining analysis indicates the apoptosis-associated
cell morphological changes expressively in MCF-7 cells. Mitochondrial
membrane potential (MMP) and reactive oxygen species (ROS) analyses
reveal that Ru
2
L3 can raise ROS levels, reduce MMP, and trigger mitochondrial dysfunction-mediated
apoptosis. The catalytic oxidation of glutathione (GSH) to its disulfide
form (GSSG) by the complexes may simultaneously increase the ROS levels,
alluding to their observed cytotoxicity and apoptosis induction. Flow
cytometry determined the quantitative classification of late apoptosis
and S-phase arrest in MCF-7 and HeLa cells. Western blotting analysis
confirmed that the complexes promote apoptosis by upregulating Caspase-3
and Caspase-9 and downregulating BCL-2. Molecular docking studies
unfolded the strong binding affinities of the complexes with VEGFR2,
an angiogenic signaling receptor, and BCL2, Cyclin D1, and HER2 proteins
typically overexpressed on tumor cells.